Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Intelligent Searching Tool Enables Biochemical Lead Identification and Patent Fortification

By BiotechDaily International staff writers
Posted on 29 Jan 2013
A new intelligent database searching system provides virtual screening to identify biologically active molecules for a broad range of applications.

Cresset Group (Welwyn Garden City, UK) completes its Cresset proV10 suite with the relaunch of its highly successful FieldScreen system as “blazeV10” for ligand based virtual screening. Based on the shape and electrostatic character of known ligands, blazeV10 rapidly searches large chemical collections for molecules with similar properties, returning diverse new leads. This makes it a powerful tool for patent fortification and compound reprofiling.

blazeV10 is used to find biologically active molecules in a broad range of situations across the pharmaceutical, agrochemical, and fine chemical industries. Performing a virtual screen with blazeV10 before a wet screening run can dramatically increase the hit rate, cutting costs and speeding up the discovery process. Applying blazeV10 to HTS results identifies molecules, which falsely failed the biological assay, rescuing them for further investigation. Using blazeV10 on compounds of known biological activity provides insights into off-target effects. Employing blazeV10 to search databases of known drugs identifies potential reprofiling opportunities. Cresset consultants use blazeV10 to advise clients on how to strengthen their patent position by identifying structurally diverse compounds that could be potential fast followers.

“The relaunch of one of our leading applications as blazeV10 completes the rebranding of the Cresset range of software for molecular design and discovery. blazeV10, sparkV10, torchV10, and forgeV10 are outstanding tools that help chemists design and discover the best new active molecules for life science research,” said Dr. Robert Scoffin, CEO of Cresset.

blazeV10 is operated through a simple web based wizard like interface or as a series of command line applications and is available as software for installation, software as a service running on cloud hardware, or through consultancy with Cresset’s project services team.

Related Links:

Cresset Group, Ltd.



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.